Capsid Allosteric Modulators Enhance the Innate Immune Response in Hepatitis B Virus-Infected Hepatocytes During Interferon Administration.
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
12
07
2021
received:
14
01
2021
accepted:
17
07
2021
pubmed:
25
9
2021
medline:
8
3
2022
entrez:
24
9
2021
Statut:
ppublish
Résumé
Capsid allosteric modulators (CAMs) inhibit the encapsidation of hepatitis B virus (HBV) pregenomic RNA (pgRNA), which contains a pathogen-associated molecular pattern motif. However, the effect of CAMs on the innate immune response of HBV-infected hepatocytes remains unclear, and we examined this effect in this study. Administration of a CAM compound, BAY41-4109 (BAY41), to HBV-infected primary human hepatocytes (PHHs) did not change the total cytoplasmic pgRNA levels but significantly reduced intracapsid pgRNA levels, suggesting that BAY41 increased extracapsid pgRNA levels in the cytoplasm. BAY41 alone did not change the intracellular interferon (IFN)-stimulated gene (ISG) expression levels. However, BAY41 enhanced antiviral ISG induction by IFN-α in HBV-infected PHHs but did not change ISG induction by IFN-α in uninfected PHHs. Compared with BAY41 or IFN-α alone, coadministration of BAY41 and IFN-α significantly suppressed extracellular HBV-DNA levels. HBV-infected human liver-chimeric mice were treated with vehicle, BAY41, pegylated IFN-α (pegIFN-α), or BAY41 and pegIFN-α together. Compared with the vehicle control, pegIFN-α highly up-regulated intrahepatic ISG expression levels, but BAY41 alone did not change these levels. The combination of BAY41 and pegIFN-α further enhanced intrahepatic antiviral ISG expression, which was up-regulated by pegIFNα. The serum HBV-DNA levels in mice treated with the combination of BAY41 and pegIFN-α were the lowest observed in all the groups. Conclusion: CAMs enhance the host IFN response when combined with exogenous IFN-α, likely due to increased cytoplasmic extracapsid pgRNA.
Identifiants
pubmed: 34558845
doi: 10.1002/hep4.1804
pmc: PMC8793994
doi:
Substances chimiques
BAY 41-4109
0
Interferon-alpha
0
Pyridines
0
Pyrimidines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
281-296Informations de copyright
© 2021 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.
Références
PLoS Pathog. 2013 Sep;9(9):e1003613
pubmed: 24068929
PLoS Pathog. 2020 Feb 14;16(2):e1008338
pubmed: 32059034
Antiviral Res. 2007 Nov;76(2):168-77
pubmed: 17709147
J Gen Virol. 2010 Aug;91(Pt 8):2080-2090
pubmed: 20375222
Virology. 1999 Oct 25;263(2):364-75
pubmed: 10544109
Gastroenterology. 2018 May;154(6):1778-1790
pubmed: 29408639
J Hepatol. 2015 Dec;63(6):1314-22
pubmed: 26216533
Antimicrob Agents Chemother. 2018 Sep 24;62(10):
pubmed: 30012770
Hepatol Commun. 2018 Nov 15;3(1):8-19
pubmed: 30619990
Viruses. 2016 Jan 14;8(1):
pubmed: 26784218
Immunity. 2015 Jan 20;42(1):123-32
pubmed: 25557055
Hepatology. 2018 Apr;67(4):1560-1599
pubmed: 29405329
Aliment Pharmacol Ther. 2020 Jan;51(2):231-243
pubmed: 31840863
Biochem Biophys Res Commun. 2008 Dec 5;377(1):248-52
pubmed: 18840406
Science. 2003 Feb 7;299(5608):893-6
pubmed: 12574631
Hepatology. 2018 Apr;67(4):1237-1252
pubmed: 29059468
Biochem Biophys Res Commun. 2011 Feb 18;405(3):405-10
pubmed: 21238430
Virology. 2012 Oct 25;432(2):452-9
pubmed: 22832122
Hepatology. 2012 Sep;56(3):803-11
pubmed: 22271421
PLoS Pathog. 2010 Jul 15;6(7):e1000986
pubmed: 20657822
Nat Rev Drug Discov. 2019 Nov;18(11):827-844
pubmed: 31455905
Biochem Biophys Res Commun. 2020 Jun 18;527(1):64-70
pubmed: 32446392
Gastroenterology. 2020 Aug;159(2):521-533.e9
pubmed: 32343960
Antiviral Res. 2014 Apr;104:118-27
pubmed: 24509240
J Hepatol. 2017 May;66(5):897-909
pubmed: 28043874
Antimicrob Agents Chemother. 1997 Aug;41(8):1715-20
pubmed: 9257747
J Clin Invest. 2012 Feb;122(2):529-37
pubmed: 22251702
J Mol Recognit. 2006 Nov-Dec;19(6):542-8
pubmed: 17006877
Antimicrob Agents Chemother. 2017 Jul 25;61(8):
pubmed: 28559265
Immunity. 2006 Sep;25(3):349-60
pubmed: 16979567
Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8138-43
pubmed: 15928089
Sci Rep. 2020 Jan 22;10(1):941
pubmed: 31969598
J Virol. 2019 Jun 14;93(13):
pubmed: 31019054
Gastroenterology. 2018 Feb;154(3):652-662.e8
pubmed: 29079518
Sci Rep. 2016 Jun 09;6:27782
pubmed: 27278060
Front Microbiol. 2018 Jul 18;9:1611
pubmed: 30072974
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
Biochem Biophys Res Commun. 2014 Sep 26;452(3):315-21
pubmed: 25150444
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
J Virol. 2000 Jun;74(12):5502-8
pubmed: 10823855